RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer comboA more recently developed, alternative method to produce polysaccharide–protein conjugates, termed bioconjugation, has been shown to simplify conjugate vaccine production and has been adopted by major pharmaceutical companies, thus making ONCY's pelareorep a very attractive biologic agent to be linked to form a pelareorep-CD3 bispecific bioconjugate for the effective treatment of various cancers.